Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) shares hit a new 52-week low on Friday. The stock traded as low as $6.00 and last traded at $6.0540, with a volume of 541,312 shares changing hands. The stock had previously closed at $6.28.
Key Headlines Impacting Ocular Therapeutix
Here are a few of the latest headlines about OCUL:
- Positive Sentiment: Ocular Therapeutix’s Phase 3 wet AMD success is a potential clinical catalyst and may support optimism about its development prospects. The articles also note that investors continue to debate how much of that opportunity is reflected in the company’s valuation. How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
- Positive Sentiment: HC Wainwright raised its price target and retained a Buy rating, while RBC Capital also kept its Buy rating. These recommendations offer a favorable analyst view, though the provided reports do not specify RBC’s target or the details of HC Wainwright’s increase. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright RBC Capital Keeps Their Buy Rating on Ocular Therapeutix
- Negative Sentiment: HC Wainwright cut its projected losses across fiscal 2026 and 2027 and several upcoming quarters, including lowering its FY2027 EPS forecast to ($1.87) from ($1.54). The revisions suggest higher expected losses and could weigh on sentiment, despite the firm’s continued Buy rating and $28 target. Ocular Therapeutix analyst estimates
Analysts Set New Price Targets
A number of equities analysts have issued reports on OCUL shares. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Monday, October 19th. Finally, UBS Group started coverage on Ocular Therapeutix in a research note on Sunday, October 11th. They issued a “buy” rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average target price of $23.83.
Ocular Therapeutix Stock Performance
The business has a fifty day moving average of $8.08 and a 200 day moving average of $8.93. The company has a market cap of $1.37 billion, a P/E ratio of -4.27 and a beta of 1.22. The company has a quick ratio of 13.03, a current ratio of 9.12 and a debt-to-equity ratio of 0.17.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The company had revenue of $12.87 million during the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business’s revenue was down 11.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.38) EPS. On average, equities analysts predict that Ocular Therapeutix, Inc. will post -1.58 EPS for the current year.
Insider Transactions at Ocular Therapeutix
In related news, insider Peter Kaiser sold 9,990 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $7.05, for a total transaction of $70,429.50. Following the transaction, the insider owned 254,388 shares in the company, valued at $1,793,435.40. The trade was a 3.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey S. Heier sold 10,869 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $76,626.45. Following the completion of the transaction, the insider directly owned 307,457 shares of the company’s stock, valued at approximately $2,167,571.85. The trade was a 3.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 98,090 shares of company stock worth $787,920. 3.10% of the stock is owned by corporate insiders.
Institutional Trading of Ocular Therapeutix
Large investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in shares of Ocular Therapeutix by 8.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,575 shares during the period. Principal Financial Group Inc. raised its position in shares of Ocular Therapeutix by 24.1% in the 1st quarter. Principal Financial Group Inc. now owns 13,623 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 2,642 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Ocular Therapeutix by 21.7% in the 2nd quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,979 shares during the period. Raiffeisen Bank International AG lifted its stake in shares of Ocular Therapeutix by 5.3% in the 2nd quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 5,000 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Ocular Therapeutix during the second quarter valued at approximately $51,000. 59.21% of the stock is owned by institutional investors.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.
Further Reading
- Five stocks we like better than Ocular Therapeutix
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
